Morepen Laboratories Limited

rs,

Subject: Investor Presentation – Q4’ FY25 Dear Sir/ Madam, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code: 500288 Please find enclosed the Investor Presentation –

73%

ness Segments: Business Segments: Pharma Business API+Rx+ConsumeR Medical Devices Point of Care 73% Share of Pharma Business 27% Share of Medical Devices FY 25 1 Executive Summary: Company Posi

27%

s: Pharma Business API+Rx+ConsumeR Medical Devices Point of Care 73% Share of Pharma Business 27% Share of Medical Devices FY 25 1 Executive Summary: Company Positioning: Company Positioning:

72%

oning: #1 80 commitment & credibility Market leaders In 6 APis Exporting to over 80 countries 72% Revenue share of API from export #1 Rx Market leaders in Gluco and BP meters fully integrated

7.4%

nsolidated revenue: consolidated revenue: Annual Revenue Rs. in Crores Rs. in Crores 1704 1830 7.4% FY'24 FY'25 2000 1500 1000 500 0 500 400 300 200 100 0 quarterly Revenue Rs. in Cror

10.1%

1000 500 0 500 400 300 200 100 0 quarterly Revenue Rs. in Crores Rs. in Crores 427 470 10.1% Q4'FY24 Q4'FY25 FY 25 2 Pharma Business FY 25 2 pHarma Business API & Forward integration:

5.8%

Pharma Business Total Pharma revenue : Annual Revenue Rs. in Crores Rs. in Crores 1261 1334 5.8% FY'24 FY'25 1400 1200 1000 800 600 400 200 0 400 300 200 100 0 quarterly Revenue R

8.5%

600 400 200 0 400 300 200 100 0 quarterly Revenue Rs. in Crores Rs. in Crores 368 338 8.5% Q4'FY24 Q4'FY25 FY 25 2 pHarma Business/API market leadership: market leadership: ProDuct R

81%

dine DesLoratadine Montelukast Atorvastatin Rosuvastatin Fexofenadine #1 #1 #1 #4 #4 #3 81% 66% 77% 30% 30% 30% *Morepen export share from India as data as per export data Others 12.4%

66%

DesLoratadine Montelukast Atorvastatin Rosuvastatin Fexofenadine #1 #1 #1 #4 #4 #3 81% 66% 77% 30% 30% 30% *Morepen export share from India as data as per export data Others 12.4% Mon

77%

oratadine Montelukast Atorvastatin Rosuvastatin Fexofenadine #1 #1 #1 #4 #4 #3 81% 66% 77% 30% 30% 30% *Morepen export share from India as data as per export data Others 12.4% Monte 22

30%

dine Montelukast Atorvastatin Rosuvastatin Fexofenadine #1 #1 #1 #4 #4 #3 81% 66% 77% 30% 30% 30% *Morepen export share from India as data as per export data Others 12.4% Monte 22.8%

“in Crores 1704 1830 7.4% FY'24 FY'25 2000 1500 1000 500 0 500 400 300 200 100 0 quarterly Revenue Rs.”

“in Crores 427 470 10.1% Q4'FY24 Q4'FY25 FY 25 2 Pharma Business FY 25 2 pHarma Business API & Forward integration: API & Forward integration: --- - API b2B Business 73% Share of Pharma Business Rx Medicines l V Consumer health ) 27% Share of Medical Devices FY 25 2 Pharma Business”

“in Crores 1261 1334 5.8% FY'24 FY'25 1400 1200 1000 800 600 400 200 0 400 300 200 100 0 quarterly Revenue Rs.”

“in Crores 114 89 74 69 FY22 FY23 FY24 FY25 65% Increase in new products Revenue over 3 years FY 25 2 pHarma Business/API increasing focus on export increasing focus on export 700 600 500 400 300 200 100 0 Export Share (API) 72.1% 67.5% 64.5% 68.63 FY22 FY23 FY24 FY25 7.6% Increase in export contribution in 3 years 700 600 500 400 300 200 100 0 Export Revenue Rs.”

“in Crores 697 636 553 556 FY22 FY23 FY24 FY25 26% Increase in export Revenue in 3 years FY 25 2 pHarma Business/API”

“America 3.4% USA 15.8% India 27.5% MENA 2.9% FY25 Asia 27.9% Europe 22.6% FY 25 2 pHarma Business/API region wise performance: region wise performance: Rs.”

“in Crores USAUSA Europe Europe India* India* APAC APAC MENA & other MENA & other 154 152 217 172 320 292 246 268 63 60 FY’24 FY25 FY’24 FY25 FY’24 FY25 FY’24 FY25 FY’24 FY25 FY 25 *Including other income 2 Pharma Business/API”

“in Crores 1000 956 989 3.5% 800 600 400 200 0 FY'24 FY'25 300 250 200 150 100 50 0 quarterly Revenue Rs.”

“in Crores 267 278 4% Q4'FY24 Q4'FY25 FY 25 2 Pharma Business/API”

“Sales Quantity (MT) Average Sales price (INR) Revenue* (Rs in crores) 500 400 300 200 100 0 476 424 304 FY23 FY24 FY25 57% Increase in quantity sold in 2 years 30000 26839 25000 20000 15000 10000 5000 0 FY23 22105 20310 FY24 FY25 1000 800 600 400 200 0 -24% Decrease in sales price in 2 years 956 989 828 FY23 FY24 FY25 19% Increase in net sales Revenue in 3 years *Including other income FY 25 2 Pharma Business/API”

Business Segments

1

Company Positioning

1

Total Pharma revenue

1

Strong Export network

1

API revenue

1

Increasing sales volumes

1

Installed API Capacity

1

Intellectual Property

1

Regulatory Approvals

1

Top selling Products

1

Business Segments

Pharma Business API+Rx+ConsumeR Medical Devices Point of Care 73% Share of Pharma Business 27% Share of Medical Devices FY 25 1 Executive Summary:

Company Positioning

#1 80 commitment & credibility Market leaders In 6 APis Exporting to over 80 countries 72% Revenue share of API from export #1 Rx Market leaders in Gluco and BP meters fully integrated mfg. for medical devices Increasing share of Formulation business Strong portfolio of consumer Health FY 25 1 Executive Summary consolidated revenue: consolidated revenue: Annual Revenue Rs. in Crores Rs. in Crores 1704 1830 7.4% FY'24 FY'25 2000 1500 1000 500 0 500 400 300 200 100 0 quarterly Revenue Rs. in Crores Rs. in Crores 427 470 10.1% Q4'FY24 Q4'FY25 FY 25 2 Pharma Business FY 25 2 pHarma Business API & Forward integration: API & Forward integration: --- - API b2B Business 73% Share of Pharma Business Rx Medicines l V Consumer health ) 27% Share of Medical Devices FY 25 2 Pharma Business

Total Pharma revenue

Annual Revenue Rs. in Crores Rs. in Crores 1261 1334 5.8% FY'24 FY'25 1400 1200 1000 800 600 400 200 0 400 300 200 100 0 quarterly Revenue Rs. in Crores Rs. in Crores 368 338 8.5% Q4'FY24 Q4'FY25 FY 25 2 pHarma Business/API market leadership: market leadership: ProDuct Rank Export* share PRODUCT share Loratadine DesLoratadine Montelukast Atorvastatin Rosuvastatin Fexofenadine #1 #1 #1 #4 #4 #3 81% 66% 77% 30% 30% 30% *Morepen export share from India as data as per export data Others 12.4% Monte 22.8% Rosu 12.3% Fexo 9.3% FY25 Lorata +Des 23.9% Atorva 19.2% API revenue split FY’25 FY 25 2 pHarma Business/API New products launched*: New products launched*: Diabetics cardiac Other Sitagliptin Linagliptin Dapagliflozin Empagliflozin SAXAGLIPTIN Ertugliflozin • • • • • • Apixaban Edoxaban rivaroxaban Olmesartan ticagrelor bempedoic acid • • • • • • *Not available for sales in the countries with valid patent resmetirom Vonoprazan Vortioxetine bexpiprazole • • • • FY 25 2 pHarma Business/API

Strong Export network

80 500 Exporting to over 80 countries top Notch cusotmers worldwide 60% Business comes from repeat cusotmers Experienced sales team for all regions Continent-wise share S. America 3.4% USA 15.8% India 27.5% MENA 2.9% FY25 Asia 27.9% Europe 22.6% FY 25 2 pHarma Business/API region wise performance: region wise performance: Rs. in Crores USAUSA Europe Europe India* India* APAC APAC MENA & other MENA & other 154 152 217 172 320 292 246 268 63 60 FY’24 FY25 FY’24 FY25 FY’24 FY25 FY’24 FY25 FY’24 FY25 FY 25 *Including other income 2 Pharma Business/API

API revenue

Annual Revenue Rs. in Crores Rs. in Crores 1000 956 989 3.5% 800 600 400 200 0 FY'24 FY'25 300 250 200 150 100 50 0 quarterly Revenue Rs. in Crores Rs. in Crores 267 278 4% Q4'FY24 Q4'FY25 FY 25 2 Pharma Business/API

Increasing sales volumes

Sales Quantity (MT) Average Sales price (INR) Revenue* (Rs in crores) 500 400 300 200 100 0 476 424 304 FY23 FY24 FY25 57% Increase in quantity sold in 2 years 30000 26839 25000 20000 15000 10000 5000 0 FY23 22105 20310 FY24 FY25 1000 800 600 400 200 0 -24% Decrease in sales price in 2 years 956 989 828 FY23 FY24 FY25 19% Increase in net sales Revenue in 3 years *Including other income FY 25 2 Pharma Business/API